Batavia Bioservices, a service provider aiding its customers in the development of complex biological medicines, has decided to launch a US facility in Woburn, Massachusetts. The company is headquarted in Leiden, The Netherlands.

Menzo Havenga, President and CEO of Batavia, said: “We have been growing more than four hundred percent in the past two years in the Netherlands and to keep up with customer demand we have decided to launch a facility in the Boston area.” Christopher Yallop, COO, adds: “We have chosen the greater Boston area due to its importance as a biotech cluster. Positioning ourselves here allows us to be close to our customers, which we deem extremely important in delivering on time and on budget.” Batavia Bioservices provides a one-stop shop from DNA cloning to Phase 1/2 clinical manufacturing for all major classes of biopharmaceuticals, including antibodies, proteins or vaccines.

“Massachusetts leads the world in life sciences thanks to our growth strategy of investing in education, innovation and infrastructure,” said Governor Deval Patrick. “We welcome Batavia Bioservices, and we look forward to working with them to create jobs and opportunities in the Commonwealth.”

The Woburn facility (± 5500 sq feet), located at Cummings Properties’ TradeCenter 128, contains multiple BSL-2 laboratories dedicated to specific tasks including Molecular Biology, mammalian cell line generation, protein production, protein purification or assay development. The company has already hired six employees for the new facility, with plans to hire four more by the end of this year.

The announcement comes as the state is preparing to host the 2012 BIO International Convention, being held June 18-21 at the Massachusetts Convention & Exhibition Center.

Date: June 13, 2012
Source: Batavia Bioservices